Soley Therapeutics has raised $75.0 million in new investment capital, marking a significant milestone for the South San Francisco-headquartered drug discovery and development company. Soley Therapeutics operates as a science-first, tech-enabled firm dedicated to uncovering first-in-class medicines. Its innovative platform leverages cells as the world’s most powerful sensors, adeptly translating the complex cellular information of stress biology into precise mechanistic insights. This unique approach allows Soley to reveal novel drug candidates that might otherwise be overlooked by conventional discovery methods, addressing critical unmet medical needs.
The company's advanced platform seamlessly integrates foundational biology with proprietary imaging and first-in-class automation. This sophisticated framework is further enhanced by full-stack AI capabilities, deployed through a strategic collaboration with Oracle, which includes OCI AI Infrastructure, NVIDIA AI Enterprise, and NVIDIA Blackwell GPUs. By combining these powerful and sophisticated tools, Soley Therapeutics has rapidly built a robust pipeline spanning critical therapeutic areas such as oncology, neurodegenerative disorders, and metabolic diseases, among others. This substantial funding round underscores investor confidence in Soley's distinctive methodology and its potential to revolutionize the landscape of drug discovery.
The newly secured capital will be instrumental in accelerating Soley Therapeutics' strategic growth initiatives. The company plans to use the funds to further advance its proprietary drug discovery platform, expand its pipeline of promising drug candidates, and scale its operational capabilities to meet future demands. This investment is expected to significantly bolster Soley's mission to bring transformative medicines to patients, driving forward its ambitious plans for continued innovation and expansion within the competitive biotechnology sector.
